J&J and AbbVie reviewed AtaiBeckley data but couldn't beat Lilly's $2.8B deal for the psychedelics company and maker of rapid-acting depression drug BPL-003.
Johnson & Johnson and AbbVie, the two pharma giants already in the psychedelic space, also eyed AtaiBeckley, according to a source familiar with the situation …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal
Weight-loss drugmaker Lilly nears $1.97 bn AtaiBeckley's acquisition: Report
Eli Lilly to acquire psychedelics-focused biotech AtaiBeckley
Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics
Eli Lilly agrees to $3.8B psychedelic buy
Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction
AtaiBeckley Shares Surge as Eli Lilly Seals $3.8B Acquisition Deal - Eli Lilly (NYSE:LLY), AtaiBeckley (N
Big Pharma And Psychedelic Medicine: Eli Lilly’s $3.8 Billion Bet
The market for psychedelic drugs to treat mental health conditions gets a big buy signal
AtaiBeckley (ATAI) Stock Skyrockets 65% After-Hours on Eli Lilly Acquisition Talks - Eli Lilly (NYSE:LLY)
Eli Lilly will acquire AtaiBeckley for up to $3.8 billion. This deal aims to develop psychedelic treatments for depression and…
Eli Lilly is reportedly negotiating to acquire psychedelic drugmaker AtaiBeckley. AtaiBeckley shares experienced a significant…
Eli Lilly will buy psychedelic drug developer AtaiBeckley for $2.8 billion upfront, showing big pharma’s increasing interest in…
Eli Lilly is buying the psychedelics-focused biotech AtaiBeckley for $2.8 billion upfront, a move that will expand its…
The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally be…
The AtaiBeckley acquisition would be the largest psychedelic deal to date.
